Atlas Trials

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Clinical trial NCT06051409 · RECRUITING

Trial details

NCT number
NCT06051409
Sponsor
Ascentage Pharma Group Inc.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Ph+ ALLLeukemia, Lymphoblastic, Acute, Philadelphia-Positive
Start date
2023-08-31
Primary completion
2027-12-31
Enrollment
350

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.